Skip to main content

Table 2 Baseline patient characteristics of the clinically suspect arthralgia patients with complete clinical follow-up (N = 152) and complete clinical follow-up as well as MRI data at baseline at 2-year follow-up (N = 98)

From: Improvement of symptoms in clinically suspect arthralgia and resolution of subclinical joint inflammation: a longitudinal study in patients that did not progress to clinical arthritis

Patient characteristicsComplete clinical follow-up (N = 152)Complete clinical follow-up and MRI data (N = 98)
Symptom resolution (n = 57)No symptom resolution (n = 95)Symptom resolution (n = 32)No symptom resolution (n = 66)
Age in years, mean (SD)44 (13)46 (13)46 (14)47 (13)
Female sex, N (%)40 (70)79 (82)20 (63)53 (80)
Family history of RA, N (%)17 (30)26 (27)10 (31)18 (27)
Symptom duration in weeks*, median (IQR)17 (9–30)17 (9–41)18 (15–32)17 (9–50)
Morning stiffness ≥ 60 min, N (%)22 (39)27 (28)10 (31)19 (29)
68-TJC*, median (IQR)5 (2–8)6 (2–12)4 (2–7)6 (2–13)
 ≥ 4 tender joints, N (%)33 (58)61 (64)18 (56)43 (65)
Increased CRP (≥ 5 mg/L), N (%)12 (21)17 (18)9 (28)10 (15)
Autoantibody status
 Negative for IgM-RF and ACPA, N (%)43 (75)71 (75)25 (78)54 (82)
 ACPA- or RF-positive, N (%)9 (16)18 (19)7 (22)12 (18)
 ACPA-positive, N (%)5 (9)6 (6)3 (9)4 (6)
  1. ACPA anti-citrullinated peptide antibody (positive if ≥ 7 U/mL), CRP C-reactive protein, IgM-RF immunoglobulin M rheumatoid factor (positive if ≥ 3.5 IU/mL), IQR interquartile range, RA rheumatoid arthritis, SD standard deviation, TJC tender joint count, VAS visual analogue scale
  2. *Missing data were as follows: symptom duration in weeks (n = 4) and 68-TJC (n = 1)